RxDoctor Payments Data

Barry Waldman, MD

Orthopaedic Surgery · Baltimore, MDNPI 1700875655

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $25,056 of the $30,076 with a category attached, or 83.3%. Encore Medical, LP accounts for 61.8% of it on its own, with 23 other manufacturers making up the rest. Reporting peaked in 2022 at $11,002 and has fallen 81.4% since, to $2,042 in 2025.

$30,076in general payments, 2019–2025

Across 80 payments — averaging $375.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Encore Medical, LP$19K
  • Medacta USA, Inc.$6K
  • Depuy Synthes Products, Inc.$2K
  • Pacira Therapeutics, Inc.$1K
  • Conformis, Inc.$1K
  • Hikma Pharmaceuticals USA$344
  • plus $1K from 18 others

What the payments were for

  • Royalty or licence$1140%
  • Consulting fees$25,05683%
  • Speaking & faculty fees$1,0003%
  • Travel & lodging$1,7386%
  • Food & beverage$2,1687%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$30,076 in reported general payments places this provider in the 85th percentile of 378 orthopaedic surgery providers in Maryland.

See all orthopaedic surgery providers in Maryland

Medicare billing

Part B allowed, 2024
$435,229
Medicare patients
683
Services billed
10,336

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Celecoxib106$2,594
Meloxicam149$1,286
Ampicillin Sodium16$1,281
Methylprednisolone69$431
Pregabalin12$237
Gabapentin30$235
Cephalexin23$76
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim11$73
Oxycodone Hcl11$67
Dexamethasone22$35

Paid to pharmacies, not to this prescriber.

Other orthopaedic surgery in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →